1-3 of 3
Xiang-Qun Xie, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inhibition of p62-ZZ Domain-Mediated Signaling Overcomes Bortezomib Resistance in Multiple Myeloma Cells Independent of Their p53 Status

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Rebecca Silberman, MD, Denise Toscani, PhD, Judith L Anderson, Nicola Giuliani, MD PhD, Xiang-Qun Xie, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4421.
https://doi.org/10.1182/blood.V130.Suppl_1.4421.4421
Published: 2017
Journal Articles

The p62-ZZ Domain Inhibitor XRK3F2 Alters Myeloma-Induced Suppression of Osteoblast Differentiation and Is Highly Cytotoxic to Myeloma Cells in Combination with Bortezomib

Rebecca Silbermann, MD, Dan Zhou, Jumpei Teramachi, DDS, PhD, Xiang-Qun Xie, PhD, G. David Roodman, MD PhD, Noriyoshi Kurihara, DDS, PhD
Journal: Blood
Blood (2014) 124 (21): 2083.
https://doi.org/10.1182/blood.V124.21.2083.2083
Published: 2014
Journal Articles

A Novel Sequestosome-1/p62 ZZ Domain Inhibitor Induces New Bone Formation In The Presence Of Myeloma In Vivo

Rebecca Silbermann, MD, Wei Zhao, MBBS, Julie L Eiseman, PhD, Jan H Beumer, PharmD, PhD, Xiang-Qun Xie, PhD, Peng Yang, PhD, Kyaw-Zeyar Myint, PhD, Lirong Wang, PhD, Zhiwei Feng, PhD, Jolene J. Windle, PhD, G. David Roodman, MD, PhD, Noriyoshi Kurihara, DDS, PhD
Journal: Blood
Blood (2013) 122 (21): 684.
https://doi.org/10.1182/blood.V122.21.684.684
Published: 2013